Trial document




This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00008796

Trial Description

start of 1:1-Block title

Title

PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

PERLES

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating
subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using
Tamsulosine LP 0.4 mg as a reference treatment.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

[---]*

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00008796
  •   2015/06/23
  •   2014/04/18
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2014-000222-38 
  •   NCT02121613  (ClinicalTrials.gov)
  •   P00048 GP 4 04  (Pierre Fabre Medicament)
  •   2014-000222-38 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Benign Prostatic Hyperplasia (BPH)
  •   N40 -  Hyperplasia of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Permixon® 160 mg
  •   Drug: Tamsulosine LP
  •   Drug: Placebo matching Permixon® 160 mg
  •   Drug: Placebo matching Tamsulosine LP
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo, Other
  •   Treatment
  •   Parallel
  •   IV
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- International Prostate Symptom Score (I-PSS score) change; time frame: Day 180; I-PSS score change from baseline to D180

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

[---]*

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Czech Republic
  •   France
  •   Germany
  •   Italy
  •   Spain
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2014/04/30
  •   900
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   45   Years
  •   85   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Male subject

- Between 45 and 85 years old

- Subject with bothersome lower urinary tract symptoms (LUTS) due to BPH such as
frequency (daytime or night time), urgency, sensation of incomplete voiding, delayed
urination or weak stream

- Subject naive to any prior treatment for LUTS due to BPH

- Prostate enlargement at digital rectal examination (DRE) suggestive of BPH

- I-PSS > 12 at enrolment visit and at inclusion visit

- QoL I-PSS score ≥ 3 evaluated at enrolment visit and at inclusion visit

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Urological history such as urethral stricture disease and/or bladder neck disease,
active (at enrolment and/or inclusion or recurrent urinary tract infection, stone in
bladder or urethra)

- Any neurologic or psychiatric disease/disorder interfering with detrusor or sphincter
muscle

- Insulin-dependent diabetes mellitus and non-controlled non insulin-dependent diabetes
mellitus

- Known severe renal insufficiency or creatinine clearance < 30 ml/mn

- Known liver insufficiency or clinically significant abnormal liver function tests

- History of, or concomitant, cardiac arrhythmia or angina pectoris

- Orthostatic hypotension at enrolment or inclusion visit

- Known hypersensitivity to one of the constituents of the study drugs

- Is participating in another clinical trial

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Pierre Fabre Medicament
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Pierre Fabre Medicament
    • Athmane BOUROUBI, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Pierre Fabre Medicament
    • Athmane BOUROUBI, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
start of 1:n-Block dynamic attributes

Additional Trial Attributes

  • Urological disease 
  • If other, please specify 
  • Study recommendations 
  • If other, please specify 
  • German director of clinical investigation 
    start of 1:1-Block address
    • [---]*
    end of 1:1-Block address
    start of 1:1-Block address contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact
  • Further contact 
    start of 1:1-Block address
    • [---]*
    end of 1:1-Block address
    start of 1:1-Block address contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact
  • Function of contact 
  • Non-interventional study 
  • Stage 
  • If other, please specify 
  • Onset of therapy 
  • If other, please specify 
end of 1:n-Block dynamic attributes
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   3
  •   2016/01/14
* This entry means the parameter is not applicable or has not been set.